1M6MYTD1Y5YMAX
Loading quotes...
Forecast
There is no analyst data available for this company.
News Go to news feed
There is currently no news available for this company. We are working on adding more providers to change this.
Financials
| (EUR) | 2022 | |
|---|---|---|
| Revenue | 0 | - |
| Gross profit | -46.61K | 96.61% |
| Net profit | -4.55M | 52.99% |
| EBITDA | -4.22M | 49.91% |
Fundamentals
| Metric | Value |
|---|---|
Market capitalization | €1.1K |
Number of shares | 127.5M |
52-week high/low | €0.00432 - €0.0000086 |
| Dividends | No |
Beta | 0.49 |
P/E ratio | 0.00 |
PEG ratio | 0.00 |
P/B ratio | 0.00 |
P/S ratio | 0.00 |
Company profile
PsyBio Therapeutics Corp. ist ein Biotechnologieunternehmen, das sich auf die Erforschung, Entwicklung und Vermarktung von psychedelisch inspirierten regulierten Medikamenten zur Behandlung von psychischen und anderen Störungen in den Vereinigten Staaten konzentriert. Der Hauptsitz des Unternehmens befindet sich in Coconut Creek, Florida.
| Name | PSYBIO THERAP. (SUB.VT.) |
| CEO | Evan Levine |
| Headquarters | Denver,
co USA |
| Website | |
| IPO | 02/25/2021 |
| Employees | 118 |
Ticker symbols
| Exchange | Symbol |
|---|---|
Pnk | PSYBF |
München | PSYB.MU |
Discover assets
Shareholders of PSYBIO THERAP. (SUB.VT.) also invest in the following assets
